It is unclear at this stage whether the Hyderabad-based vaccine maker’s decision to terminate its November 24 contract with Precisa Medicamentos and Envixia Pharmaceuticals is a result of the controversy.
While the government said details on the quantity of doses to be imported to India by Cipla are still under consideration, The Indian Express has learnt that the vaccine is initially expected to be provided to India in limited quantities — as donations by the US drug maker.
The results of the phase 3 trials come a day before the Hyderabad company’s scheduled meeting with the World Health Organization (WHO), where it is expected to submit its proposal for an Emergency Use Listing of the vaccine.
Trials in the UK have found a monoclonal antibody cocktail effective in some patients with severe Covid-19. What is this treatment, how does it compare with plasma therapy, and how much promise does it hold?
The Maryland-headquartered company said its vaccine had demonstrated 100 per cent protection in late-stage trials against moderate and severe disease caused by SARS-CoV-2 — a boost for the prospects of its Indian version, Covovax.
Ocugen, Bharat Biotech’s Covaxin partner in the US, “will no longer pursue an Emergency Use Authorization” of the vaccine in that country, the American clinical stage biopharmaceutical company told Nasdaq on Thursday.
Sources at the IT Ministry said though the issue had been handled for now, CERT-In, with help of other domestic and global cybersecurity experts, was checking the entire CoWin platform once again to ensure there were no vulnerabilities.
When the Centre began vaccination in January, it procured 11 million doses of Covishield at Rs 200 each excluding taxes, and about 5.5 million doses of Covaxin at Rs 206 each excluding taxes. However, the prices were later negotiated downwards to Rs 150 per dose.
India is considering whether people can be given a mix of different Covid-19 vaccine doses. What can be the merits of such a programme, and what are the concerns? Which other countries are trying this?
India has placed an advance order for 300 million doses of Corbevax. How does this Covid-19 vaccine work, and how does it differ from others? What could the order mean for India’s vaccination programme?
The company on Friday received Drug Controller General of India Dr V G Somani's permission to manufacture batches of Sputnik V “for test and analysis”, a source close to the development told The Indian Express on condition of anonymity.
The move, which would make it easier for companies to bring their vaccines to India, follows similar demands raised by, among others, Pfizer and Cipla during negotiations to supply imported vaccines to the country.